CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 449 enrolled
Drug / intervention
Vareniclinedrug
Likely dose
Varenicline 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01836276
NCT01836276Phase 4Completed
CompareCT.gov

Understanding Disparities in Quitting in African American and White Smokers

Nikki Nollen, PhD, MA·interventional·Posted Apr 19, 2013·Updated Oct 24, 2018

In Brief

A Phase 4 clinical trial evaluating Varenicline for Smoking Cessation. Completed, enrolled 449 participants across 2 sites.

Detailed Summary

The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Pfizer

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2013
Enrollment StartFeb 1, 2013
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.2 years ago

Interventions

Vareniclinedrug

1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines